Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. To fulfill that mission our world class team of cell therapy pioneers and experts is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.
We will be good stewards of our investors’ capital and seek to deliver superior returns on their investment.
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. To fulfill that mission our world class team of cell therapy pioneers and experts is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.
We will be good stewards of our investors’ capital and seek to deliver superior returns on their investment.
Chimeric Therapeutics was founded in 2020 by Paul Hopper.
Chimeric Therapeutics Pty Limited
Chimeric Therapeutics trades on the ASX (Australian Stock Exchange).
Chimeric is traded under the stock symbol CHM.
The company’s initial public offering was on January 18, 2021.
The company’s fiscal year ends on June 30th.
Chimeric does not offer a direct purchase plan for investors. You may purchase Chimeric stock through a licensed securities broker.
Please email IR@chimerictherapeutics.com for assistance with investor relations questions
